---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-017859"
form_type: "8-K"
ticker: "ALEC"
cik: "0001653087"
company_name: "Alector, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:16:16.371220+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Alector Q1 net loss $45.9M, cash $669.3M; on track for latozinemab INFRONT-3 regulatory engagement in mid-2023

## Summary
- Revenue $16.5M (down $8M YoY); net loss $45.9M ($0.55/share) vs $44.6M ($0.54/share) in Q1 2022.
- Cash, equivalents and investments $669.3M; management expects runway through 2025.
- On track to discuss INFRONT-3 (latozinemab in FTD-GRN) with regulators mid-2023; data readout early 2025.
- Received $17.8M milestone from AbbVie for AL002 LTE enrollment; INVOKE-2 top-line data expected Q4 2024.
- 2023 guidance: collaboration revenue $15-25M, R&D expense $225-245M, G&A $60-70M.

## SEC filing metadata
- accession: 0000950170-23-017859
- form_type: 8-K
- ticker: ALEC
- cik: 0001653087
- company_name: Alector, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1653087/000095017023017859/0000950170-23-017859-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1653087/000095017023017859/alec-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-017859
- JSON: https://secwatch.observer/filing/0000950170-23-017859.json
- Plain text: https://secwatch.observer/filing/0000950170-23-017859.txt

## Key facts
- Earnings Releases
  Alector, Inc. reported financial results for the quarter ended March 31, 2023.
  - Period: the quarter ended March 31, 2023
  - Result: reported results
  source text: On May 4, 2023, Alector, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1653087/000095017023017859/0000950170-23-017859-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.